PELOTON THERAPEUTICS, INC.

Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.  Peloton Therapeutics’ lead program, PT2385, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of renal and other cancers.

rccimage

Click above image for video discussing Peloton’s HIF-2a inhibitor.

Peloton Therapeutics Launches Ubiquitin Ligase Research Platform

June 15, 2017, 8:00 AM Eastern Daylight Time

Peloton Therapeutics, Inc., a drug discovery and development company focused on advancing novel small molecule cancer therapies, announced today it has entered into an exclusive agreement with the University of Texas Southwestern Medical Center and Deepak Nijhawan, M.D., Ph.D. to conduct sponsored research into ubiquitin ligases. This research will be conducted in the interest of developing potential therapies designed to thwart cancer progression in a manner unlike conventional small molecule approaches.

>>More